Outcome of etoposide and mitoxantrone for relapsed or refractory acute myeloid leukemia (RR-AML) in the modern era.

被引：0
|
作者：
Bowman, Zelia Ramone Karema
Caddell, Ryan James
Kanate, Abraham Sebastian
Shillingburg, Alex
Shah, Nilay Arvind
Craig, Michael
Cumpston, Aaron
机构：
[1] West Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] West Virginia Univ, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e18515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18515
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia
    Zhong, Sharon
    Kurish, Heena
    Walchack, Robert
    Li, Hong
    Edwards, Jessi
    Singh, Abhay
    Advani, Anjali
    LEUKEMIA RESEARCH, 2024, 139
  • [2] Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).
    Grunwald, Michael Richard
    Boselli, Danielle
    Bohannon, Lauren M.
    Zimmerman, Michael Keith Alister
    Ai, Jing
    Knight, Thomas Gregory
    Ragon, Brittany K.
    Plesca, Dragos
    Trivedi, Jigar S.
    Avalos, Belinda Rene
    Copelan, Edward Alan
    Symanowski, James Thomas
    Gerber, Jonathan Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
    Stahl, Maximilian
    Podoltsev, Nikolai A.
    DeVeaux, Michelle
    Perreault, Sarah
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Fathi, Amir T.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Brunner, Andrew
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark
    Vey, Norbert
    Verma, Vivek
    Germing, Ulrich
    Fernandez, Pau Montesinos
    Zelterman, Daniel
    Kim, Tae Kon
    Prebet, Thomas
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2016, 128 (22)
  • [4] MITOXANTRONE AND ETOPOSIDE - AN EFFECTIVE REGIMEN FOR REFRACTORY OR RELAPSED ACUTE MYELOGENOUS LEUKEMIA
    LAZZARINO, M
    MORRA, E
    ALESSANDRINO, EP
    ORLANDI, E
    PAGNUCCO, G
    MERANTE, S
    BERNASCONI, P
    INVERARDI, D
    BONFICHI, M
    BERNASCONI, C
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 43 (05) : 411 - 416
  • [5] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    BLOOD, 2016, 128 (22)
  • [6] Burden of relapsed/refractory (RR) acute myeloid leukemia.
    Panjabi, Sumeet
    Hines, Dionne M.
    McGuiness, Catherine Balderston
    Yucel, Emre
    Yea, Steven
    McIver, Zachariah
    Wade, Rolin L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
    Deveaux, Michelle
    Stahl, Maximilian
    Montesinos, Pau
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Barnard, John
    Podoltsev, Nikolai A.
    Brunner, Andrew M.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark R.
    Fathi, Amir T.
    Perreault, Sera
    Kim, Tae Kon
    Prebet, Thomas
    Vey, Norbert
    Verma, Vivek
    Germing, Ulrich
    Bergua, Juan
    Serrano, Josefina
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [8] Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort
    Stahl, Maximilian
    Deveaux, Michelle
    Montesinos, Pau
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Majhail, Navneet S.
    Podoltsev, Nikolai A.
    Fathi, Amir T.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Brunner, Andrew M.
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark R.
    Perreault, Sera
    Kim, Tae Kon
    Prebet, Thomas
    Vey, Norbert
    Verma, Vivek
    Kobbe, Guido
    Bergua, Juan
    Serrano, Josefina
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [9] MITOXANTRONE AND CONSTANT INFUSION ETOPOSIDE FOR RELAPSED AND REFRACTORY ACUTE MYELOCYTIC-LEUKEMIA
    PACIUCCI, PA
    DAVIS, RB
    HOLLAND, JF
    MARTELO, O
    SCHIFFER, CA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (06): : 516 - 519
  • [10] Efficacy and safety of mitoxantrone and etoposide (ME) in refractory and relapsed acute nonlymphocytic leukemia
    Pourtsidis, AG
    Baka, M
    Stasinopoulou, A
    Varvoutsi, M
    Paidoussi, C
    Bouhoutsou, D
    Kosmidis, HV
    INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, 1998, 5 (01): : 7 - 11
12345